Lessons learned from the fate of AstraZeneca's drug pipeline¶
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014). Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Reviews Drug Discovery, 2005-2010.
Cited by¶
1 citation across 1 artifact.
Domain-specific¶
- Riskiest Assumption Test
- AstraZeneca's "5R framework," introduced around 2011 and documented by Cook and colleagues in Nature Reviews Drug Discovery (2014), is a field deployment of the same ordering discipline in pharmaceutical R&D.
Supported in partVerified against the work's full text
“The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential.”
- AstraZeneca's "5R framework," introduced around 2011 and documented by Cook and colleagues in Nature Reviews Drug Discovery (2014), is a field deployment of the same ordering discipline in pharmaceutical R&D.
Verification¶
Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:f836923e6dcd · see in the full table